AstraZeneca Pharma India (BOM:506820) Total Liabilities : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India Total Liabilities?

AstraZeneca Pharma India's Total Liabilities for the quarter that ended in Dec. 2024 was ₹0 Mil.

AstraZeneca Pharma India's quarterly Total Liabilities increased from Jun. 2024 (₹0.00 Mil) to Sep. 2024 (₹5,619.50 Mil) but then declined from Sep. 2024 (₹5,619.50 Mil) to Dec. 2024 (₹0.00 Mil).

AstraZeneca Pharma India's annual Total Liabilities increased from Mar. 2022 (₹3,451.70 Mil) to Mar. 2023 (₹3,961.80 Mil) but then declined from Mar. 2023 (₹3,961.80 Mil) to Mar. 2024 (₹3,661.10 Mil).

AstraZeneca Pharma India Total Liabilities Historical Data

The historical data trend for AstraZeneca Pharma India's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India Total Liabilities Chart

AstraZeneca Pharma India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

3,419.20

3,185.40

3,451.70

3,961.80

3,661.10

AstraZeneca Pharma India Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															-	3,661.10	-	5,619.50	-

AstraZeneca Pharma India Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AstraZeneca Pharma India's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3571.2	+	(27.8	+	9.2370555648813E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	62.1	+	0)
	=	3,661

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	10780.3	-	7119.2
	=	3,661

AstraZeneca Pharma India's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	N/A

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	N/A	-	N/A
	=	N/A

AstraZeneca Pharma India Total Liabilities Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Pharma India Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » Total Liabilities

Traded in Other Exchanges

ASTRAZEN:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines.

AstraZeneca Pharma India Headlines

No Headlines